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Abstract  
Lipid based drug delivery systems have been widely studied and reported over the past decade and offer a 
useful alternative to other colloidal drug delivery systems. Skin is a popular route of drug delivery for 
locally and systemically acting drugs and nanoparticles are reported as a potential formulation strategy for 
dermal delivery. Although the skin acts as a natural physical barrier against penetration of foreign materials, 
including particulates, opportunities exist for the delivery of therapeutic nanoparticles, especially in 
diseased and damaged skin and via appendageal routes such as the openings of hair follicles. The extent 
and ability of nanoparticles to penetrate into the underlying viable tissue is still the subject of debate 
although recent studies have identified the follicular route as the most likely route of entry; this influences 
the potential applications of these dosage forms as a drug delivery strategy. This paper reviews present 
state of art of lipid-based nanocarriers focussing on solid lipid nanoparticles, nanostructured lipid carriers 
and nanoemulsions, their production methods, potential advantages and applications in dermal drug 
delivery. 
Keywords: Skin, skin penetration, solid lipid nanoparticles, dermal delivery, colloidal carriers, 
nanostructured lipid carriers, nanoemulsions, dermal applications   
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1. INTRODUCTION 
 
Nanoparticulate drug delivery systems have attracted lot of attention as a consequence of their unique size-dependent 
properties. Among various types of nanoparticles developed for pharmaceutical applications, lipid nanoparticles are 
considered advantageous due to their versatility and biocompatibility. Recent advances, leading to the production of 
nanoparticles of uniform size and shape, offer the possibility for development of new therapeutics with potential for 
drug targeting, controlled and site-specific drug delivery and have resulted in a large number of studies exploring their 
interaction with the skin. This paper focuses on a range of lipid based nano-systems, i.e., solid lipid nanoparticles 
(SLNs), nanostructured lipid carriers (NLCs), nanoemulsions (NEs), their structure and associated features, advantages 
and their use in dermal drug delivery systems.  
1.1 Skin as a target site for particle delivery 
Skin is an attractive route of delivery for local and systemic delivery of drugs and is a potential route for nanoparticles 
to gain entry into the body. The skin, however, affords a natural physical barrier against particle penetration, but there is 
the potential to deliver nanoparticles for therapeutic applications, especially via disruptions in the barrier afforded by 
hair follicles and to diseased or damaged skin. 
1.1.1 Skin structure 
The skin is the largest organ of the body and functions as a protective layer preventing entry of harmful xenobiotics into 
the body (Fig 1), however, its large surface area and ready accessibility render it an attractive route for drug delivery. 
The skin structure can be broadly categorized into the non-viable epidermis called stratum corneum (SC), the viable 
epidermis and dermis. It is the outermost SC layer that affords the barrier properties of the skin and it regulates the flux 
of chemicals and fluids between the external environment and the body [1,2]. 
1.1.2 Transport through skin 
Molecules generally penetrate the SC by two separate routes [3], with hydrophilic entities following a transcellular 
pathway and more lipophilic solutes traversing via the intercellular lipids. The diffusion of drug through skin may also 
occur through appendages in the skin such as the hair shaft and sweat glands. These appendages are breaches in the 
continuity of the SC barrier, thus presenting follicular or shunt pathways for absorption. The follicular pathway has, 
until recently, been considered as making a negligible contribution to uptake due to the relatively small percentage of 
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the skin surface covered in hairs, normally around 0.1% [4]. The follicular route has gained renewed interest being 
reported as the predominant pathways for nanoparticle entry [5,6], but also as a route for hydrophilic drugs and 
potentially for larger molecules such as polar steroids that would not normally be expected to cross the skin easily [7].  
 
2. LIPID DRUG DELIVERY SYSTEMS 
Lipid based drug delivery systems are an established, proven and commercially exploitable strategy for the formulation 
of pharmaceuticals intended for oral, topical, parenteral and pulmonary delivery. Lipid nanoparticles display interesting 
properties at the nanoscale level suitable for therapeutic applications and are attractive for medical purposes due to these 
important and unique features; these include their large surface to mass ratio, which is much larger than that of other 
colloidal particles and their ability to bind, adsorb or carry other compounds. Lipid drug delivery systems will perform 
differently depending on the interplay between the formulation characteristics and route of administration such as 
dermal, pulmonary and parenteral routes [8–11].  
Lipid based nanocarriers possess following advantages [12,13]: 
• The ability to improve stability of pharmaceuticals 
• The feasibility to carry both lipophilic and hydrophilic drugs 
• Manufacturing is relatively easy to scale-up and sterilize 
• Most of the lipids used are biodegradable, biocompatible and non-toxic 
• The ability to control and target drug release 
• They are generally less expensive than polymeric/surfactant based carriers 
 
 
2.1 Solid lipid nanoparticles 
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SLNs were developed as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles for 
controlled drug delivery. [14]. These particles are solid, sub-micron particulate carriers ranging in size from 1 to 1000 
nm. They consist of a mixture of physiological and biodegradable or biocompatible lipids, suitable for the incorporation 
of both lipophilic and hydrophilic drugs within a lipid matrix and are stabilized using surfactants. Generally, lipids used 
in preparation of SLNs are highly purified triglycerides, complex glyceride mixtures or even waxes [15,16]. There are 
three main models (Fig 2) for the incorporation of bioactive components into SLNs: (1) homogenous matrix model (2) 
bioactive-enriched shell model (3) bioactive enriched core model. The type of structure obtained depends upon the 
components of the formulation such as the HLB of lipids, bioactive compounds, the surfactant used and production 
methods employed. A homogenous matrix is usually obtained when adopting cold homogenization methods or when 
extremely lipophilic drugs are incorporated into SLNs using hot homogenization techniques. The drug is then released 
from such formulations by a dissolution-controlled mechanism. If phase separation occurs during the cooling process 
from the liquid oil droplets a bioactive enriched shell type may result; such formulations show a burst release of active 
compound. Conversely, a bioactive-enriched core may be formed when the opposite phenomenon occurs, which means 
the drug starts precipitating first and therefore, the shell has reduced amounts of encapsulated components. Drug release 
from these formulations is governed by a membrane-controlled release mechanism following Fick’s law of diffusion 
[17]. 
2.1.1 Production method 
There are several different methods reported in literature for production of SLNs. These methods are high pressure 
homogenization [16,18,19], microemulsion technique [20], emulsification-solvent evaporation [16], emulsification-
solvent diffusion method [21], solvent injection or solvent displacement method [22], phase inversion [23], multiple 
emulsion technique [24], ultrasonication [25] and membrane contractor technique [26]. High-pressure homogenization 
techniques have several perceived benefits over other methods, e.g. easy scale up, reduction in requirements for organic 
solvents and relatively short production times, thus this method is often used in many pharmaceutical applications. Both 
hot and cold high-pressure homogenization techniques can be used to produce lipid nanoparticles. During hot 
homogenization methods, the drug loaded lipid phase is melted and mixed with an aqueous emulsifier phase using a 
high shear process. Usually, homogenization at elevated temperatures results in smaller particle sizes due to reduced 
viscosity of the inner phase due to the temperatures required. However, elevated temperatures can potentially accelerate 
degradation of drug and/or the carrier. Cold homogenization has been developed to overcome such problems associated 
with hot homogenization and to address uneven drug distribution within the aqueous phase during homogenization. In 
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cold homogenization methods, the drug is combined with the molten lipid and rapidly cooled using dry ice or liquid 
nitrogen. Once solidified, the drug-/ lipid mixture can then be milled to form microparticles. The resultant 
microparticles are suspended in a cold surfactant solution which is homogenized at, or below, ambient temperature to 
produce the nanoparticles [27,28]. 
 
2.2 Nanostructured lipid carriers 
Second generation lipid carriers, namely nanostructured lipid carrier (NLCs), were developed by Radtke and Müller 
(2001) to overcome some limitations associated with SLNs, such as low encapsulation efficiency and the risk of drug 
expulsion during storage due to an increasing purity of lipid [29]. Compared to SLNs, NLCs have a reduced water 
content and a higher drug loading capacity for many active compounds within the particle suspension and the potential 
expulsion of active compounds during storage is minimised [30,31]. For NLCs, the particles are produced using a blend 
of solid lipid with liquid lipid but are based on the preparation methods described for SLNs [32]. In NLCs, a major 
portion of the oil constitutents of the O/W emulsion is replaced by a solid lipid leading to a solid particle matrix at body 
temperature [33,34]. To obtain NLCs, solid lipids are blended with the oily liquid lipids preferably in ratios ranging 
from 70:30 up to 99.9:0.1 [35]. 
 
 Depending on production method and the composition of the formulations, NLCs can be further classified as follows, 
[17,33,36]: 
 
A) Imperfect type NLCs: These NLCs have an imperfectly structured solid matrix. Such imperfections can be increased 
by using glycerides composed of different fatty acids e.g. differing in the length of C-chain or a mixture of saturated 
and unsaturated acids. The disordered crystal accommodates more drug molecules, either in a molecular form or as 
amorphous clusters of drug (fig. 3A). 
B) Amorphous type NLCs: The phenomenon of crystallization can lead to expulsion of drug from the formulation. In 
order to reduce this, NLCs can be prepared by maintaining the polymorphicity of the lipid matrix by mixing solid lipids 
with specialised lipids such as hydroxyoctacosanylhydroxystearate,  isopropyl palmitate or medium chain triglycerides. 
(fig. 3B).  
C) Multiple type NLCs: These are oil-in-lipid-in-water type NLCs. The solubility of lipophilic compounds is higher in 
liquid lipids (oils) compared to solid lipids. Based on this principle, multiple type NLCs can be developed. In this type 
of NLC, a larger than normal amount of oil is  combined with the solid lipids (fig. 3C). Inclusion of the oil, in excess of 
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its solubility, leads to phase separation, producing small, oily nano-compartments sorrounded by the solid lipid matrix. 
This reduces drug leakge from the system and  facilitates controlled release.  
 
 
 
 
2.3 Nanoemulsions 
Nanoemulsions (NEs) are nanoscale droplets of therodynamically stable dispersions of two immiscible liquids, such as 
oil and water, stabilized by an interfacial film of surfactant molecules [37,38]. They are normally oil-in-water emulsions 
with mean droplet diameters ranging from 50 – 1000 nm. NEs differ from microemulsions such as due to their smaller 
droplet size; most NEs are optically transparent in contrast to microemulsions due to the droplet size being smaller than 
the wavelength of visible light. Microemulsions cause multiple scattering of visible light and hence have a white opaque 
appearance [39,40].  
 
Nanoemulsions can be differentiated into three types based on the composition of dispersed phase and continous phase 
[41]: 
 
• Oil-in-water nanoemulsions where oil droplets are dispersed in the continous aqueous phase 
 
• Water-in-oil nanoemulsions where water droplets are dispersed in the continous oil phase 
 
• Bi-continous nanoemulsions where microdomains of oil and water are interdispersed within the system 
 
Nanoemulsions possess many advantages such as rapid and efficient penetration of the drug, improved solubility of 
lipophilic drugs and the same emulsion can carry both lipophilic and hydrophilic drugs. They are non-toxic and non-
irritant, hence they can be applied easily to skin and mucous membranes and can be incorporated into a variety of 
formulations such as foams, creams, liquids, sprays [42,43]. 
 
2.3.1 Production methods 
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Nanoemulsions can be most effectively produced using high-pressure equipment. The most common methods used to 
produce nanoemulsions are high-pressure homogenization and microfluidization. They can also be prepared using 
ultrasonication and emulsification [44,45].  
In high-pressure homogenization methods, mixture of oil, surfactant and aqueous phase.is passed through narrow gap 
(in the range of few microns) under high pressure ( 100 – 2000 bar). The fluid accelerates over short distances under 
very high shear stresses and the cavitation forces break apart the particles forming submicron entities. The operating 
pressure and number of times the coarse pre-emulsion is cycled through the microfludizer or homogenizer will 
influence the particle size of the nanoemulsion produced [46,47]. 
 
3. NANOCARRIERS FOR DERMAL DRUG DELIVERY 
 
Topical delivery of compounds through the skin has been documented throughout history, but it is only since 1970’s 
with the successful of transdermal patches, that the route has widely explored for systemic delivery of drugs. 
Investigating the extent and possible mechanism of nanoparticle penetration through skin is key to being able to fully 
exploit these carriers for therapeutic purposes. Topical application of these nanocarriers, especially lipid nanoparticles, 
has reported benefits for both local effects in the skin (affording the opportunity to deliver drug to the epidermis and 
dermis) and systemic activity, achieved by drug permeation into deeper skin layers and transdermally [48]. They can 
also cause formation of a film on the skin surface, thus enhancing occlusion and affecting skin permeation, 
 
There is still much debate in the literature regarding the mechanism of penetration of nanoparticles through the skin, for 
example concern about how nanometer-sized particle can penetrate the SC membrane via a much smaller intercellular 
space. There is similar uncertainty regarding the predominant factors governing penetration and the underlying 
mechanisms involved [49]. Although there are several reports of penetration and accumulation of nanocarriers in the 
surface layers of the SC, such nanocarriers have shown a mixed ability to improve drug penetration deeper into skin 
[50]. A more promising approach for nanocarrier dermal drug delivery is follicular targeting. The shunt pathway via 
follicles is a significant route for penetration, especially for nanoparticles which can target hair follicles [51].  
In the hair follicles, the follicular infundibulum effectively increases the surface area and presents as a disruption of the 
epidermal barrier towards the lower parts of the follicle; it additionally functions as a reservoir for drugs and carriers 
[52]. Follicles are deep invaginations within the skin where the SC is thinner and the vascularization is denser. There 
are a number of potential sites within the hair follicle for targeting for both therapeutic and cosmetic applications [53]. 
Additionally, drug delivery can be targeted to sebaceous gland associated with hair follicles for the therapy of acne, 
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androgenetic alopecia and other sebaceous gland dysfunctions. A further target site is the bulge region, located deep 
within the follicles and is reported to be a reservoir of keratinocyte stem cells [54]. Hence, follicluar drug delivery 
provides a route to bypass the intact SC and drugs may reach dermis by entering the follicles and then passing through 
the sebaceous gland or penetrating into the epithelium of the follicular sheath [55]. It is difficult to differentially 
distinguish the route of entry of drugs and nanoparticles into the skin as most in vitro techniques use a diffusion cell 
model and the total amount of drug either delivered into, or through, the skin is quantified. Such techniques can be 
adapted to study follicular transport using an adapted stripping method [53]. Following normal tape stripping processes 
(normally 10-15 successive applications of an adhesive tape), to remove the SC, a cyanoacrylate glue is applied to the 
stripped surface and covered with a further adehsive tape layer. Once removed, this glue layer can be used to determine 
follicular deposition. The sectioning of skin for use in diffusion cells may cause a reduction in transport via the 
follicular route due to sectioning of elsatic fibres which maintain integrity of the follicles. 
 
In recent years, attention have been directed towards lipid-based colloidal carriers since it is obvious that these lipid 
carriers are often a preferred drug delivery system for dermal drug delivery [56]. There have been numerous studies and 
patents exploiting the topical delivery of lipid-based colloid systems, formulated into different structures for various 
disease treatments, and for either local or systemic delivery [57].  
 
3.1 Lipid nanoparticles as a carrier in dermal applications 
 
A variety of lipophilic and hydrophilic drugs such as antimicrobials, antifungals and challenging compounds like 
proteins and peptides have been entrapped into lipid nanoparticles. Lipid nanoparticles can then be further incorporated 
into a cream, hydrogel or ointment to obtain semisolid formulation suitable for application to the skin.  
 
It has been claimed that SLNs systems give improved UV absorbance, which is of great significance in the cosmetic 
industry. A lipophilic amine (stearylamine) was used in the SLNs formulation to improve encapsulation efficiency of 
tretinoin using an ion-pairing mechanism [58]. Organic solvents were avoided and the SLNs were stable for extended 
periods. Skin irritation, assessed using a rhino mouse model, was reduced compared to a marketed tretinoin cream. 
Tretinoin derivatives, isotretinoin, retinol and  vitamin A palmitate have also been incorporated into SLNs for topical 
application. The isotretinoin loaded SLNs were relatively small, 30 – 50 nm in size, with encapsulation efficiencies of 
up to 99.7% depending on the concentration of surfactant used in the formulation [59]. Retinol was also incorporated 
into SLNs with a larger particle size of > 200 nm [60]. The skin retention of retinol in a procine model was found to be 
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0.9 µg higher (over 6 h) compared to nanoemulsion control group. Vitamin A palmitate has been formulated into SLNs 
of 350 nm [61]. The pharmacokinetics of this formulation were determined in human cadaver skin with Keshary Chien 
cells. Drug release from SLNs was 67.5% after 24 h compared with 54.4% for the gel control. Lipid nanoparticles were 
investigated as a delivery system for prednicarbate. Santos et al. reported  an improved extent of prednicarbate uptake 
using prednicarbate loaded SLNs in human skin in vitro [62]. There was improved uptake of the corticosteroid 
following application of SLNs compared to conventional corticosteroid cream or ointment. A similar strategy can also 
be applied to topical nanoparticles for antimicrobial delivery. Silver nanoparticles have been incorporated to wound 
dressings to exploit its antimicrobial activity and several commercial products are available. Safety concerns regarding 
the application of silver in this way have been recently outlined dicussed in detail [63]. The use of other types of 
antimicrobial nanoparticles is less well studied and may prove a useful alternative to silver. Miconazole-containing 
SLNs were prepared using a hot homogenisation method and demonstrated a higher skin penetration compared to a 
control gel formulation in an ex vivo study using excised human cadaver skin [64]. Similarly econazole nitrate has been 
incorporated into SLNs [65]. The particles had a high encapsulation efficiency (97-102%), diameters ranging between 
140 ± 13 and 154 ± 5 nm and demonstrated an abiliity to control drug release as well as increase skin penetration. NLCs 
containing the lipophilic antifungal agent clotrimazole were shown to have higher encapsulation efficiences than similar 
SLNs  due to their liquid components, but both seemed suitable for topical delivery remaining stable over extended 
periods [66]. Dermal abosprtion of cyproterone acetate, used for topical acne treatment, was incorpoated into a range of 
different nanoparticles inlcuding SLNs, NLCs and NEs. Although activity was reduced in cell lines, skin penetration of 
the drug associated with SLNs was four times higher than a control cream formulation in excised human skin. A dermal 
targetting effect was shown, with only low levels found in the dermis, thus reducing the potential for systemic 
absorption and side-effects [67].  
 
Delivery of lipid soluble bioactive compounds can be challenging, especially in aqueous based preparations. Omega-3 
fatty acids, the major essential fatty acids, are susceptible to oxidative deterioration and it has been shown that 
encapsulation of these acids is a strategy that can be used to improve stability [68,69]. There are current challenges 
facing the development of carotenoids as nutraceutical compounds due to their relatively poor water solublity, high 
melting points and chemical instability which can be overcome by incorporating them within the oil phase in NEs [70]. 
It has been shown that NLCs were able to encapsulate such lipohilic drugs and improve their stability and 
bioavailability [71]. NLCs have major applications in cosmetic applications which require a high crystallinity of the 
carrier (e.g. UV protection) [72]. COX-2 selective anti-inflamamatory drugs such as celecoxib and valecoxib have been 
incorporated into NLC-based systems. Joshi et al. compared an NLCs based gel of celecoxib with a micellar gel of the 
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same composition and measuring in vitro skin penetration using rat skin and the pharmacodynamic efficiency by 
Aerosil induced rat paw oedema. The in vitro permeation of  celecoxib from the NLCs gel was less than the permeation 
from the micellar based gel, which confirms the findings about nanoparticles leading to a drug deposit in the skin 
resulting in sustained release. The in vivo comparison of the percentage edema inhibition produced by NLC and 
micellar gel showed a significant higher inhibition after application of the NLCs based gel up to 24 h [73]. 
Indomethacin, a potent non-steroidal anti-inflammatory drug, is widely used topically for the treatment of dermatitis 
and rheumatic diseases. Ricci et al. investigated the in vitro penetration of indomethacin from NLCs containing gel 
through the SC and epidermis, the in vivo indomethacin release by tape-stripping test and the in vivo anti-inflammatory 
activity using the UV-B induced erytherma model. It was found that the anti-inflammatory effect was prolonged for 
indomethacin-loaded NLC gel compared to a control gel formulation [74]. 
 
Nanoemulsions have been shown to effectively deliver recombinant proteins or inactivated organisms to mucosal 
surfaces to produce an immune response. The first applications of this, an influenza vaccine and an HIV vaccine,  are in 
clinical trials and further are on going for vaccines including Hepatitis B and anthrax [75–77].  In vivo studies have 
shown that a NEs incorporating clobetazol propionate for psoriasis and atopic dermatitis is safe for human use and was 
not irritant to the skin [78].  
 
A variety of different animal models has been used to evaluate percuatneous delivery of molecules; these include 
porcine, mouse, rat and guinea pig models. To evaluate dermal absorption of a molecule, the most relevant membrane is 
human skin. Skin from various sources, including cosmetic surgery and amputations, has been used for the in vitro 
determination of percutaneous penetration. However, the availability of human skin can be limited and animal skin is 
therefore frequently used. The most appropriate model for human skin is the pig due to its histological and biochemical 
properties which have been shown repeatedly to be similar to human skin; thus excised porcine skin is widely accepted 
as an in vitro model suitable for passive diffusion studies  [79]. Specifically, porcine ear skin shows most similarities 
along with a similar follicular structure with  hairs and infundibula extending deep into the dermis, as in humans. As 
live porcine models are not a common laboratory model, rodents such as mice, rats are commonly used in in vivo 
percuteneous permeation studies. The advantages of such models are their small size, uncomplicated handling and 
relatively low cost [80].  A nanoemulsion formulated with eucalyptus oil, for example, has been studied for its wound 
healing and skin irritation activity in Wistar rats. Results indicated that the formulation was non-irritant and resulted in a 
faster wound contraction rate with respect to a control and a neomycin treated  rat  [81,82]. Thus animal models, other 
than porcine, can have some roles in the drug development process, e.g. for screening delivery systems and carriers only 
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selected data have shown a reasonable correlation with human skin. Similarly, tissue cultured human skin and 
equivalents generally present a lower barrier to drug uptake and so are of limited use in permeation studies [83].   
 
Conclusions 
 
The exploitation of biocompatible excipients makes the application of lipid nanoparticles an attractive proposition for 
drug delivery. The importance of skin penetration, particularly via skin appendages, and more specifically the hair 
follicles, has opened new applications for these products with the potential to specific skin penetration pathways using 
suitable formulations for targeting various sites in skin. The ability to incorporate drugs into lipid nanocarriers offers the 
opportunity to develop new carriers for drug delivery that could be used for both passive and active drug targeting. 
However, there is little consistency with regard to the type of drug delivered with nanoparticles and future work needs 
to be carried out for better understanding of nanoparticle-SC interactions.  
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Fig. (2) Lipid nanoparticles models, homogenous matrix (left), bioactive enriched shell model (middle), bioactive 
enriched core model (right). 
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Fig. 3(A) Highly imperfect NLC 
   
                     
Fig. 3(B) Amorphous type NLC 
 
 
                      
Fig. 3(C) Multiple type NLC 
 
 
 
 
 
 
 
 
 
 
